RANKINGS
Lowest P/S — Healthcare
Price-to-Sales ratio measures valuation relative to revenue.
180 companies with P/S Ratio data.
Ranked by P/S Ratio(180)
| # | Ticker | Name | Market Cap | P/S Ratio |
|---|---|---|---|---|
| 1 | MTEX | $9M | 0.1 | |
| 2 | NAII | $17M | 0.1 | |
| 3 | AVD | $75M | 0.1 | |
| 4 | VHI | $399M | 0.2 | |
| 5 | SNYR | $7M | 0.2 | |
| 6 | BHC | $2.1B | 0.2 | |
| 7 | LFVN | $53M | 0.2 | |
| 8 | BTMD | $60M | 0.3 | |
| 9 | COTY | $2.0B | 0.3 | |
| 10 | RMTI | $37M | 0.4 | |
| 11 | ALTO | $376M | 0.4 | |
| 12 | KRO | $748M | 0.4 | |
| 13 | USNA | $342M | 0.4 | |
| 14 | QDEL | $1.2B | 0.4 | |
| 15 | EPC | $1.0B | 0.5 | |
| 16 | OLN | $3.2B | 0.5 | |
| 17 | FMC | $2.2B | 0.5 | |
| 18 | SCL | $1.2B | 0.5 | |
| 19 | MYGN | $459M | 0.5 | |
| 20 | AMTX | $155M | 0.6 | |
| 21 | ACNT | $127M | 0.7 | |
| 22 | GOVX | $3M | 0.8 | |
| 23 | LXFR | $354M | 0.9 | |
| 24 | EMN | $8.4B | 1.0 | |
| 25 | TLRY | $805M | 1.0 | |
| 26 | FUL | $3.4B | 1.0 | |
| 27 | KYNB | $30M | 1.0 | |
| 28 | CHRS | $270M | 1.0 | |
| 29 | NATR | $469M | 1.0 | |
| 30 | CBT | $3.9B | 1.0 | |
| 31 | IOSP | $1.9B | 1.1 | |
| 32 | SMG | $3.6B | 1.1 | |
| 33 | AVNT | $3.5B | 1.1 | |
| 34 | MTX | $2.3B | 1.1 | |
| 35 | GURE | $8M | 1.1 | |
| 36 | SEE | $6.2B | 1.2 | |
| 37 | BMRA | $6M | 1.2 | |
| 38 | HRTX | $177M | 1.2 | |
| 39 | OPK | $888M | 1.2 | |
| 40 | CPIX | $48M | 1.3 | |
| 41 | SRPT | $2.3B | 1.3 | |
| 42 | AMRN | $305M | 1.3 | |
| 43 | FTLF | $87M | 1.4 | |
| 44 | CSBR | $80M | 1.4 | |
| 45 | MGNX | $222M | 1.5 | |
| 46 | SLSN | $78M | 1.5 | |
| 47 | LFCR | $195M | 1.5 | |
| 48 | TOMZ | $12M | 1.5 | |
| 49 | PPG | $24.7B | 1.6 | |
| 50 | IFF | $18.5B | 1.6 | |
| 51 | NEUP | $25M | 1.6 | |
| 52 | FSI | $67M | 1.7 | |
| 53 | AGEN | $181M | 1.8 | |
| 54 | CLX | $12.6B | 1.8 | |
| 55 | SGMO | $106M | 1.8 | |
| 56 | PAHC | $2.4B | 1.8 | |
| 57 | RPM | $13.9B | 1.9 | |
| 58 | LXU | $994M | 1.9 | |
| 59 | EL | $27.6B | 1.9 | |
| 60 | NL | $287M | 2.0 | |
| 61 | NVAX | $1.4B | 2.0 | |
| 62 | IPAR | $3.1B | 2.1 | |
| 63 | TEVA | $37.0B | 2.1 | |
| 64 | CYRX | $496M | 2.2 | |
| 65 | REX | $1.4B | 2.2 | |
| 66 | CRIS | $25M | 2.3 | |
| 67 | NEOG | $2.1B | 2.3 | |
| 68 | SIGA | $328M | 2.4 | |
| 69 | PFE | $154.2B | 2.4 | |
| 70 | BMY | $118.6B | 2.5 | |
| 71 | SXT | $4.0B | 2.5 | |
| 72 | UG | $30M | 2.5 | |
| 73 | ROG | $2.1B | 2.6 | |
| 74 | ICCC | $70M | 2.6 | |
| 75 | BIIB | $26.3B | 2.7 | |
| 76 | DTIL | $187M | 2.7 | |
| 77 | ANIP | $1.8B | 2.9 | |
| 78 | MNKD | $846M | 3.0 | |
| 79 | FTK | $568M | 3.0 | |
| 80 | JAZZ | $12.4B | 3.0 | |
| 81 | RIGL | $580M | 3.2 | |
| 82 | CL | $67.5B | 3.4 | |
| 83 | HXL | $6.4B | 3.4 | |
| 84 | PTCT | $6.0B | 3.5 | |
| 85 | LNTH | $5.4B | 3.5 | |
| 86 | PLX | $190M | 3.6 | |
| 87 | CDXS | $215M | 3.6 | |
| 88 | CHD | $22.6B | 3.6 | |
| 89 | BMRN | $10.7B | 3.7 | |
| 90 | NAGE | $376M | 3.8 | |
| 91 | CRVO | $37M | 3.8 | |
| 92 | ACAD | $3.8B | 3.9 | |
| 93 | ABT | $175.6B | 4.0 | |
| 94 | PG | $335.5B | 4.0 | |
| 95 | MRKR | $27M | 4.0 | |
| 96 | TKNO | $162M | 4.3 | |
| 97 | ALB | $22.4B | 4.4 | |
| 98 | WDFC | $2.8B | 4.4 | |
| 99 | FENC | $215M | 4.5 | |
| 100 | NBIX | $13.1B | 4.6 |
How to turn this ranking into valuation work
Start with the company page
Validate business quality, margins, capital structure, and the current valuation context before relying on a single multiple.
Then validate WACC
A cheap multiple does not guarantee a sensible discount rate. Check cost of capital before finalizing DCF assumptions.
Finish with DCF
Use the matching DCF page to test intrinsic value so multiples, discount rates, and cash-flow assumptions stay connected.
P/S Ratio Rankings in Other Sectors
Data updated daily · Source: SEC EDGAR, Polygon.io